Abstract
Introduction
In 2006, the type 2 diabetes market, valued at over $12 billion in the US,
Europe, and Japan, was dominated by the two blockbuster PPAR-gamma agonists,
Takeda' s Actos and GlaxoSmithKline' s Avandia. Nine existing drug classes,
including the recently introduced GLP-1 analogues and the DPP-IV inhibitors,
make for a crowded and competitive market; nonetheless, significant unmet
clinical need exists and provides an attractive commercial opportunity for new
treatments that demonstrate superior efficacy and safety over currently
available treatments. A total of 14 new agents--including four new GLP-1
analogues, four new DPP-IV inhibitors, and the novel SGLT inhibitors--are set
to enter the market before 2011. The launch of these drugs, as well as
increased uptake of Eli Lilly' s Byetta (exenatide) and Merck' s Januvia
(sitagliptin), will impact current diabetes treatment and contribute to
revenue growth, driving the type 2 diabetes market to reach over $18 billion
in 2011.
Questions Answered in This Report
- - Takeda led the type 2 diabetes market in 2006, with a market share of
nearly 25%; followed closely by GlaxoSmithKline with over 20%. How will
Takeda secure its dominant market position over the forecast period? How will
GlaxoSmithKline fare in the type 2 diabetes market following the Avandia
controversy?
- - Primary care physicians have a myriad of treatment options for type 2
diabetes and will see the emergence of several novel agents launching over the
forecast period. What do physicians identify as the key attributes of
currently marketed agents? What are the perceived advantages and/or
disadvantages of emerging therapies versus available therapies?
- - PPAR-gamma agonists are currently blockbusters in type 2 diabetes
therapy; however, developing GLP-1 analogues, DPP-IV inhibitors, and novel
SGLT inhibitors have the potential to radically change the diabetes market
dynamic. What products are being developed in the major competitors'
pipelines? How will emerging drugs perform if approved for type 2 diabetes
treatment?
- - 2005 saw the launch of Eli Lilly' s first-in-class GLP-1 analogue,
Byetta, and Merck' s first-in-class DPP-IV inhibitor, Januvia, launched in
2006. How has the availability of these novel agents altered physicians'
prescribing habits, and which competing brands will be most affected?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Competitive Analysis: Detailed discussion of major competitors
including Takeda, GlaxoSmithKline, Novo Nordisk, Eli Lilly, and Amylin; other
competitors Bristol-Myers Squibb, Sanofi-Aventis, Novartis, and Merck; and the
emerging competitors Metabolex, Daiichi Sankyo, Boehringer Ingelheim, and
Roche. Included is an analysis of each company' s diabetes product portfolio,
strategic positioning, and development pipeline in type 2 diabetes. The report
features an in-depth discussion of leading brands including sales and market
position, SWOT analysis, and strategy initiatives.
- Physician Perception of Key Brands: Analysis of physician
perceptions of the type 2 diabetes market based on a custom survey of 50
US-based primary care physicians. The survey is brand-focused and examines
physician perceptions of key competitors, brand attributes, messaging, and
uptake of emerging agents.
- Epidemiology: Total prevalent and diagnosed cases for each of the
major markets are presented in an annualized forecast from 2006 to 2011.
- Market Forecast: Annualized sales forecasts for branded agents
presented by region, drug class, molecule, and brand for 2006 to 2011,
including the uptake of new agents.
|
Related Report
|
View Cart
